Viewing Study NCT05104905


Ignite Creation Date: 2025-12-25 @ 3:30 AM
Ignite Modification Date: 2025-12-26 @ 2:11 AM
Study NCT ID: NCT05104905
Status: WITHDRAWN
Last Update Posted: 2022-05-11
First Post: 2021-10-22
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Sponsor: Faron Pharmaceuticals Ltd
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module